|
Tetralogy of Fallot
|
0.610 |
GeneticVariation
|
disease |
BEFREE |
The six pathogenic variations were identified on the genes CHD7 (CHARGE syndrome), CITED2 (tetralogy of Fallot, ventricular septal defect and atrial septal defect), ZFPM2 (tetralogy of Fallot), MYH6 (atrial septal defect, familial isolated dilated cardiomyopathy) and, in two cases, KMT2D (Kabuki syndrome).
|
29536580 |
2018 |
|
Tetralogy of Fallot
|
0.610 |
Biomarker
|
disease |
MGD |
The essential role of Cited2, a negative regulator for HIF-1alpha, in heart development and neurulation.
|
12149478 |
2002 |
|
Tetralogy of Fallot
|
0.610 |
SusceptibilityMutation
|
disease |
ORPHANET |
|
|
|
|
Tetralogy of Fallot
|
0.610 |
Biomarker
|
disease |
HPO |
|
|
|
|
ATRIAL SEPTAL DEFECT 8
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Variations of CITED2 are associated with congenital heart disease (CHD) in Chinese population.
|
24848765 |
2014 |
|
ATRIAL SEPTAL DEFECT 8
|
0.500 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
ATRIAL SEPTAL DEFECT 8
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
The present study assessed the effects of CITED2 silencing on macrophage recruitment in two xenograft mouse models of human breast cancer, one in which tumor growth was sensitive to CITED2 silencing (MDA-MB-231) and one in which it was insensitive (MDA-MB-468).
|
29399152 |
2018 |
|
Neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
Here, we show that CITED2 silencing significantly attenuated MDA-MB-231 primary tumor growth concordant with reduced tumor vascularization, while MDA-MB-468 primary tumor growth and tumor vascularization remained unaffected.
|
28008154 |
2017 |
|
Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Extending these studies to human breast cancer, it was observed that CITED2 mRNA expression was significantly elevated in patient specimens of metastatic breast cancer relative to primary tumors, with highest levels in metastasis to bone relative to non-bone sites.
|
27216153 |
2016 |
|
Neoplasms
|
0.360 |
Biomarker
|
group |
BEFREE |
Moreover, lentivirus-based CITED2 silencing sensitized HeLa cell line-derived tumor xenografts to cisplatin in immune-deficient mice.
|
26384430 |
2015 |
|
Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
In CEA/Tag mice, LBH589 induced tumor-cell expression of CITED2 and increased the efficacy of anthracycline to reduce tumor growth.
|
22465428 |
2012 |
|
Neoplasms
|
0.360 |
Biomarker
|
group |
CTD_human |
Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
|
21660965 |
2011 |
|
Neoplasms
|
0.360 |
AlteredExpression
|
group |
BEFREE |
Both NCOR2 and CITED2 mRNA levels were associated with MFS, that is, tumour aggressiveness, independently of traditional prognostic factors.
|
19904269 |
2009 |
|
Malignant Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
The role of CITED2 has been investigated in a number of malignancies; however, the roles of this protein in gastric cancers remain unclear.
|
28501104 |
2017 |
|
Malignant Neoplasms
|
0.330 |
Biomarker
|
group |
BEFREE |
The CITED2/p300/p53/ERCC1 pathway is thus involved in the cell response to cisplatin and represents a potential target for cancer therapy.
|
26384430 |
2015 |
|
Malignant Neoplasms
|
0.330 |
AlteredExpression
|
group |
BEFREE |
We found the CBP/p300-interacting transactivator with glutamic acid/asparagine-rich carboxy-terminal domain 2 (CITED2) to be specifically upregulated in UC-associated cancer cell lines by BA treatment, at both mRNA and protein expression levels.
|
21165656 |
2011 |
|
Malignant Neoplasms
|
0.330 |
Biomarker
|
group |
CTD_human |
In the present study, we examined whether CITED2 is also involved in the resistance of cancer cells to the chemotherapeutic drug cisplatin.
|
21660965 |
2011 |
|
Ventricular Septal Defects
|
0.310 |
Biomarker
|
group |
BEFREE |
They also indicate that smad2, cited2, and p300 may play important roles in modulating the confirmation of ventricular septal defects.
|
23899608 |
2013 |
|
Heart Septal Defects
|
0.310 |
Biomarker
|
group |
CTD_human |
In summary, the observation of these mutations in patients with septal defects indicates that CITED2 has a causative impact in the development of CHD in humans.
|
16287139 |
2005 |
|
Heart Septal Defects
|
0.310 |
GeneticVariation
|
group |
BEFREE |
In summary, the observation of these mutations in patients with septal defects indicates that CITED2 has a causative impact in the development of CHD in humans.
|
16287139 |
2005 |
|
Ventricular Septal Defects
|
0.310 |
Biomarker
|
group |
CTD_human |
|
|
|
|
Benign Neoplasm
|
0.300 |
Biomarker
|
group |
CTD_human |
Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis.
|
21660965 |
2011 |
|
Muscular Atrophy
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
These results suggest that the gain of Cited2 function counteracts glucocorticoid-induced muscle atrophy through inhibition of proteolysis mediated by p300-dependent gene transcription.
|
19032942 |
2009 |
|
Neurogenic Muscular Atrophy
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
Overexpression of the transcriptional coregulator Cited2 protects against glucocorticoid-induced atrophy of C2C12 myotubes.
|
19032942 |
2009 |